Related references
Note: Only part of the references are listed.The unique presentation of SARS-CoV-2 Infection in patients with B-cell depletion: definition of 'persistent inflammatory sero-negative COVID'
Ana Belkin et al.
CLINICAL MICROBIOLOGY AND INFECTION (2023)
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
Pengfei Li et al.
CELL RESEARCH (2022)
Treatment of chronic or relapsing COVID-19 in immunodeficiency
Li-An K. Brown et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Nature does things well
[Anonymous]
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
A. Jayk Bernal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
Emi Takashita et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Jennifer Hammond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
R. L. Gottlieb et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Christina Y. Lee et al.
CANCER DISCOVERY (2022)
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients
V. Dinah Parums
MEDICAL SCIENCE MONITOR (2022)
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro et al.
LEUKEMIA (2022)
COVID-19 therapeutics: Challenges and directions for the future
Philip C. Robinson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
The immunology and immunopathology of COVID-19
Miriam Merad et al.
SCIENCE (2022)
Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies
Ferenc Magyari et al.
ANNALS OF HEMATOLOGY (2022)
Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
Hao Zhou et al.
VIRUSES-BASEL (2022)
Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic
Giulia Garzi et al.
FRONTIERS IN IMMUNOLOGY (2022)
T-cell responses and therapies against SARS-CoV-2 infection
Salman M. Toor et al.
IMMUNOLOGY (2021)
Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient
Ji Hoon Baang et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
SARS-CoV-2 persistence and non-protective immunity in infected haematological patients
Karolina Akinosoglou et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response
Ana Zabalza et al.
EUROPEAN JOURNAL OF NEUROLOGY (2021)
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Anne Mea Spanjaart et al.
LEUKEMIA (2021)
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
D. M. Weinreich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Anil Gupta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient
Yukiko Nakajima et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2021)
COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge
Anna Furlan et al.
FRONTIERS IN IMMUNOLOGY (2021)
LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
Myron J Levin et al.
Open Forum Infectious Diseases (2021)
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani et al.
LANCET (2021)
The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study
Chiara Sepulcri et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
SARS-CoV-2 Antiviral Therapy
Kaiming Tao et al.
CLINICAL MICROBIOLOGY REVIEWS (2021)
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Per Ljungman et al.
LEUKEMIA (2021)
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Evdoxia Kyriazopoulou et al.
NATURE MEDICINE (2021)
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
M. Dougan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo- controlled phase 3 trial
Vincent C. Marconi et al.
LANCET RESPIRATORY MEDICINE (2021)
The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
Per Ljungman et al.
BONE MARROW TRANSPLANTATION (2020)
COVID-19 illness in native and immunosuppressed states: A clinical?therapeutic staging proposal
Hasan K. Siddiqi et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
Phil-Robin Tepasse et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Francesco Passamonti et al.
LANCET HAEMATOLOGY (2020)
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy
Marie Helleberg et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19
Lars F. Westblade et al.
CANCER CELL (2020)
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
Abi Vijenthira et al.
BLOOD (2020)
Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer
Victoria A. Avanzato et al.
CELL (2020)
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Bina Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer
Teresa Aydillo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)